Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Montelukast Efficacy in the Treatment of Refractive Uremic Pruritus
Brief Summary: In this study hemodialysis patients that underwent dialysis thrice weekly screen for uremic pruritus and 80 patients that at least have refractive pruritus that lead to sleep and daily activity disorders enroll in this study. These patients should have at least a course of therapy without proper response. After proper informing patients and taking testimonial patients enter to study. Then patients randomized in case and control group. In case group, patients took montelukast 10 milligram daily and in control group took placebo for 30 days. Other antipruritic or antiinflammatory medication has been stopped one week prior to starting treatment. Calcium, phosphorous, urea, creatinine, highly sensitive CRP (hsCRP), Parathyroid Hormone (PTH), hemoglobin and kt/V were measured at beginning and at end of study. pruritus severity assessed by Detailed Pruritus Score that introduced by Duo and Visual Analogue Score in beginning and at end of study in both group. Sleep disorder score and its severity added to crude score at beginning and end of study and change of measures analyzed.


Options:
A: Arm Label: CR845 0.5mcg/kg; Type: EXPERIMENTAL; Interventions: Drug: CR845 0.5 mcg/kg | Arm Label: CR845 1 mcg/kg; Type: EXPERIMENTAL; Interventions: Drug: CR845 1 mcg/kg | Arm Label: CR845 1.5mcg/kg; Type: EXPERIMENTAL; Interventions: Drug: CR845 1.5mcg/kg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CR845 0.5 mcg/kg; Assigned to Arm(s): CR845 0.5mcg/kg | Intervention Type: DRUG; Name: CR845 1 mcg/kg; Assigned to Arm(s): CR845 1 mcg/kg | Intervention Type: DRUG; Name: CR845 1.5mcg/kg; Assigned to Arm(s): CR845 1.5mcg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: hemodialysis+hemoperfusion (HA330); Type: EXPERIMENTAL; Interventions: Other: hemodialysis only, Other: hemodialysis plus hemoperfusion(HA330) | Arm Label: hemodialysis+hemoperfusion (HA130); Type: EXPERIMENTAL; Interventions: Other: hemodialysis only, Other: hemodialysis plus hemoperfusion(HA130) | Arm Label: hemodialysis only; Type: ACTIVE_COMPARATOR; Interventions: Other: hemodialysis only | Intervention Type: OTHER; Name: hemodialysis only; Assigned to Arm(s): hemodialysis only, hemodialysis+hemoperfusion (HA130), hemodialysis+hemoperfusion (HA330) | Intervention Type: OTHER; Name: hemodialysis plus hemoperfusion(HA330); Assigned to Arm(s): hemodialysis+hemoperfusion (HA330) | Intervention Type: OTHER; Name: hemodialysis plus hemoperfusion(HA130); Assigned to Arm(s): hemodialysis+hemoperfusion (HA130)
C: Arm Label: montelukast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): montelukast | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Sarna Lotion; Type: EXPERIMENTAL; Interventions: Drug: Sarna | Arm Label: Placebo Cetaphil lotion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cetaphil | Intervention Type: DRUG; Name: Sarna; Assigned to Arm(s): Sarna Lotion | Intervention Type: DRUG; Name: Cetaphil; Assigned to Arm(s): Placebo Cetaphil lotion

Answer: C